Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop the production process for the recombinant sCD83 protein for large-scale production, utilizing ...
VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...
IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission ...
Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. “With ...
MaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing Efficiency
MaxCyte, Inc. and Oribiotech Ltd. have announced a strategic collaboration to improve efficiency and scalability in cell therapy manufacturing. This partnership will integrate MaxCyte's ExPERT™ ...
Trinity Biotech plc, a biotechnology company focusing on human diagnostics and diabetes management, has announced a significant update to its Comprehensive Transformation Plan, which includes ...
Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback